SCYNEXIS, Inc.

SCYX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013
Revenue $257.0K $257.0K $257.0K $1.3M $16.9M
Cost of Revenue — — — $15.4M $16.3M
Gross Profit — — — $3.6M $552.0K
Gross Margin — — — 284.9% 3.3%
Operating Expenses
Research & Development $18.3M $20.1M $16.4M $8.3M $4.4M
SG&A Expense $8.3M $8.0M $12.2M $7.6M $4.4M
Operating Income $-26.3M $-27.8M $-28.3M $-14.6M $-7.2M
Operating Margin -10,241.2% -10,823.7% -11,030.7% -1,166.2% -42.7%
Interest Expense $1.5M $351.0K $-11.0K $48.0K —
Pretax Income $-25.1M $-30.0M $-28.3M $-6.8M —
Income Tax Expense $0 $0 $0 $-1.2M $0
Net Income $-25.1M $-30.0M $-32.6M $-4.2M $-30.5M
Net Margin -9,751.0% -11,668.9% -12,693.8% -337.1% -180.7%
EPS (Basic) $-0.94 $-1.58 $-2.68 $-1.04 $-69.74
EPS (Diluted) — $-1.58 $-2.68 $-2.69 $-69.74
Shares Outstanding (Basic) 29.0M 19.0M 12.2M 5.7M 671.2K
Shares Outstanding (Diluted) 29.0M 19.0M 12.2M 5.9M 671.2K
Dividends Per Share — — — — —
← Newer Page 2 of 2 Older →